The stock market saw some fluctuations on Monday, with Viking Therapeutics, Inc. (NASDAQ:VKTX) experiencing a gap down as its shares opened at $36.59, lower than the previous close of $37.42. The stock traded at $37.15, with a volume of 683,248 shares.
Analysts have been closely monitoring VKTX, with StockNews.com upgrading Viking Therapeutics to a ‘sell’ rating on February 9th. William Blair also reissued an ‘outperform’ rating for the company. Additionally, Stifel Nicolaus and Maxim Group have both increased their price targets for VKTX, indicating positive prospects for the biotech firm.
Amidst these developments, the market continues to observe promising weight-loss drugs from biotechs, further contributing to the dynamic landscape of the stock market.
